Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Auxilium Pharmaceuticals Inc Narrows FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates


Wednesday, 6 Nov 2013 07:00am EST 

Auxilium Pharmaceuticals Inc updated its previously announced guidance for fiscal 2013 and now expects total revenues in the range of $370 million to $401 million (prior fiscal 2013 revenue guidance was in the range of $363 million to $405 million). According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $383 million for fiscal 2013.